Skip to main content
Molecular Therapy logoLink to Molecular Therapy
. 2024 Oct 10;32(11):4160–4162. doi: 10.1016/j.ymthe.2024.10.002

VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction

Yujuan Dong, Jiaxun Jade Liu, Yunfei Zhou, Wei Kang, Shanglin Li, Alvin HK Cheung, Yi Hu, Rui Liao, Nathalie Wong, Chi Chun Wong, Simon SM Ng , Jun Yu ∗∗
PMCID: PMC11573568  PMID: 39389063

Main text

(Molecular Therapy 32, 4045–4057; November 2024)

In the original Figure 1 of this article, the schematic diagram of generation Vstm2a whole-body knockout mice was incorrect. The authors have used CRISPR/Cas9, but not Cre-LoxP system, for the deletion of exon 2-3 of Vstm2a gene. This error does not affect other figures or the conclusions of this paper. The authors sincerely apologize for any inconvenience the error may have caused.

graphic file with name gr1o.jpg

Figure 1. Heterozygous knockout of Vstm2a promotes CRC development in an AOM/DSS mouse model (original)

graphic file with name gr1c.jpg

Figure 1. Heterozygous knockout of Vstm2a promotes CRC development in an AOM/DSS mouse model (corrected)

Contributor Information

Simon S.M. Ng, Email: simonng@surgery.cuhk.edu.hk.

Jun Yu, Email: junyu@cuhk.edu.hk.


Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES